Clinical Perspectives on the Role of Hormone Therapy in Menopausal Management

A supplement to Ob.Gyn. News.
This supplement is based on physician interviews. It is supported by Kenwood Therapeutics, a division of Bradley Pharmaceuticals, Inc.

To view the supplement, click the image above.

Topic Highlights

• Menopause and Hormone Therapy

• The Cardiovascular Paradox

• Current Recommendations for Postmenopausal Hormone Therapy

• Effective Low-Dose Therapy

• Clinical Trial of Transdermal Estrogen

• Other Considerations of Transdermal Hormone Therapy

Faculty/Faculty Disclosures

Donna Shoupe, MD
Professor, Department of Obstetrics and Gynecology
Keck School of Medicine
University of Southern California
Dr. Shoupe is on the advisory board of Bradley Pharmaceuticals, Inc.
Steven R. Goldstein, MD
Professor of Obstetrics and Gynecology
New York University School of Medicine
Dr. Goldstein has disclosed that he is on the advisory boards of Bradley Pharmaceuticals, Inc., Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Novogyne Pharmaceuticals, Novo Nordisk, and Pfizer Inc.

With Comments From:
Daniel R. Mishell, Jr., MD
Lyle G. McNiele Professor
Department of Obstetrics/Gynecology
Keck School of Medicine
University of Southern California
Dr. Mishell has disclosed that he is a consultant to Barr Pharmaceuticals, Inc., and Bayer Healthcare Pharmaceuticals Inc.
Alfred Moffett Jr., MD, FACOG
Clinical Assistant Professor, Obstetrics and Gynecology
University of South Florida College of Medicine
OB-GYN Associates of Mid-Florida, P.A.
Dr. Moffett is on the advisory board of Bradley Pharmaceuticals, Inc.
Lee P. Shulman, MD, FACOG, FACMG
Professor and Chief
Division of Reproductive Genetics
Department of Obstetrics and Gynecology
Feinberg School of Medicine
Northwestern University
Dr. Shulman is on the advisory board of Bradley Pharmaceuticals, Inc.

Copyright © 2007 by Elsevier Inc.